Search

everythinglearnresearchcommunity

for

Search:↓

Upadacitinib improved multiple immune-related conditions in one patient.

Women and people with skin of color are more likely to be misdiagnosed with alopecia areata.

A standard protocol for alopecia areata clinical trials was created to improve consistency and encourage more research.

Combined light therapy improves eye health and quality of life for those with meibomian gland dysfunction.

The gel improves hair regrowth and reduces irritation in alopecia areata treatment.

EDA signaling is linked to skin disorders, various cancers, and liver disease.

Baricitinib is effective and safe for treating alopecia areata in Korea.

Intralesional triamcinolone is more effective than cryotherapy for treating alopecia areata in middle-aged adults.

Combining baricitinib with low-dose corticosteroids significantly improved severe hair loss in eight patients.

Restoring hair follicle immune privilege may help treat alopecia areata.

Higher CD8+ T cell levels are linked to Alopecia areata in Iraqi patients.

Alopecia areata is a hair loss disease caused by complex immune reactions, and new targeted treatments show promise.

Low-dose naltrexone and platelet-rich plasma can regrow hair in lichen planopilaris.

Monochromatic light devices, especially the 308-nm excimer laser, are promising for treating alopecia areata but more research is needed.

Fibrosing alopecia in a pattern distribution is a type of hair loss that may often be overlooked, especially in men.

Diffuse alopecia areata causes widespread hair thinning due to an autoimmune response.

A 50 mg non-loading dose of ritlecitinib is safe for adults and adolescents.

Combining low-level laser therapy with scalp microneedling and a clobetasol solution significantly improves androgenetic alopecia.

Linalool in fragrances may harm hair follicles and contribute to hair loss.

Olumiant® (Baricitinib) is effective for treating hair loss from Alopecia Areata.

Dutasteride, usually used for prostate issues and hair loss, could potentially treat Amyotrophic Lateral Sclerosis (ALS) due to its neuroprotective, antioxidant, and anti-inflammatory properties, but more testing is needed.

Adults with alopecia areata stick to their medication better than those with atopic dermatitis.

Continuous baricitinib is needed to keep hair regrowth in severe alopecia areata.

Apremilast helps regrow hair in hard-to-treat alopecia areata.

Blocking IL-12/IL-23p40 helped reverse severe hair loss in patients.

Oral ritlecitinib and baricitinib are promising treatments for severe alopecia areata due to their balance of effectiveness and safety.

Ritlecitinib improves hair regrowth in alopecia areata over 24 months.

Early diagnosis and multidisciplinary care, including orthopedic surgery, can prevent long-term disability in IFAP syndrome.

Apremilast did not work for treating severe alopecia areata.

Ritlecitinib effectively treats alopecia areata and is well-tolerated.